An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...

PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...

Findings support model in which accelerated biological aging of mammary epithelia may underpin breast cancer susceptibility ...

Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...

TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...

Bottom Line: A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient’s risk of hepatocellular carcinoma (HCC), ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

New cfDNA test enables multicancer detection with high accuracy, offering a cost effective approach for early diagnosis and ...

Head and neck cancers represent a biologically heterogeneous group of malignancies requiring accurate diagnosis, staging, and risk stratification for ...